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The aim of the study was to assess the incidence and survival rates of soft tissue sarcomas (STSs) in children 0–14 years of age
in Moscow Region, Russian Federation. The database of childhood population-based cancer registry of Moscow Region was
used as a data source. Tumors were stratiﬁed according to International Classiﬁcation of Childhood Cancer, 3d ed. Sixty-eight
cases of STS were registered from 2000 to 2009. Crude incidence rate was 0,78, and age-standardized incidence rate using World
Standard Population was 0,81 per 100.000 children/year. The highest age-speciﬁc incidence was observed in infants: 1,76 per
100.000 children/year. Rhabdomyosarcoma (RMS) was the most common histological type comprising 54,4% of all STS. 5-year
observed survival (OS) of all patients with STS was 64,1 (95%CI 55,0–73,2). There was no statistically signiﬁcant diﬀerence in OS
between RMS—59,2 (95%CI47,0–71,4) and nonrhabdomyosarcoma STS—69,3 (95%CI55,8–82,8) (P = 0.63). Incidence and
survival rates of STS observed in the study were comparable to the other Eastern European countries.
1.Introduction
Soft tissue sarcomas (STSs) represent a heterogeneous
groupofneoplasmsoriginatingfromprimitivemesenchymal
cells [1]. Population-based data suggest that these tumors
comprise 4–8% of all cancer cases in patients under the
age of 15 years [2–4]. STSs represent the second most
common extracranial solid tumor in children in Europe and
the USA following neuroblastoma [3, 4]. STSs are divided
into two distinct groups: rhabdomyosarcoma (RMS) and
nonrhabdomyosarcoma STS (NRSTS) [1]. RMS is the single
mostfrequentchildhoodSTS,accountingformorethan50%
of cases. NRSTS represents biologically and clinically het-
erogeneousassortmenttumors.Distributionofsubgroupsof
STS is age dependent. RMS is more common in children less
than 10 years of age whereas NRSTS predominates in older
age groups [1].
Large international epidemiological studies have shown
that the incidence of STS varies in diﬀerent geographic
regions and ethnic groups [2]. STS epidemiology in children
in Russian Federation (RF) has not been adequately studied
due to several reasons. The nationwide system of cancer
registration established in RF in 1953 stratiﬁes malignancies
by topography of primary tumor. International classiﬁca-
tions speciﬁcally designed for children (e.g., International
Classiﬁcation of Childhood Cancer, 3d eds.—ICCC-3) and
based on the histogenesis of tumors are not currently used
for data analysis and reporting. At the same time STS in
childhood can occur in a wide range of primary sites and
are of many histological types. Moreover, there is a lack of
information on the survival rates of children with cancer
in RF. In order to overcome these limitations a childhood
population-based cancer registry was established in Moscow
Region (MR) in 2000.
Theaimofthisstudyistodescribeincidenceandsurvival
rates of STS in children 0–14 years old in MR for the period
from 2000 to 2009. The data were analyzed for the whole
group of STS and separately for RMS and NRSTS subgroups.2 Sarcoma
2.MaterialsandMethods
Data on patients were retrieved from the database of child-
hood population-based cancer registry of MR that has
prospectively registered all cancer cases in children 0–14
years old since 2000. MR is located in the central part
of RF and occupies 46.000km2 with total population of
6,6 million (2008). The region is divided in 72 municipal
districts (okrug) which are clustered in 12 medical districts.
Moscow city is not an administrative part of the region, and
its territory is not covered by the cancer registry of MR.
All patients 0–14 years old with STS diagnosed in 2000–
2009 were included in analysis. Case ﬁnding of patients
diagnosedbefore2000allowedtoexcludeprevalentcasesand
include in the ﬁnal analysis patients with STS diagnosed in
2000.Thelagtimefromdiagnosistorecordingintheregistry
was estimated to be less than 1 year.
Multiplesourcesofinformationonnewcancercaseswere
used and included but not limited to discharge letters from
cancer hospitals, data from pathology laboratories, and from
general cancer registry of Moscow Region. By the national
lawoncologistsareobligedtoﬁllanotiﬁcationformonevery
newly diagnosed case of cancer. The cancer registry has an
access to the database of Ministry of Healthcare of Moscow
Region that contains information on patients referred to fed-
eral cancer centers. The cancer registry closely collaborates
withprimarycarepediatricians.Notiﬁcationformsfornewly
diagnosed patients and for patients who ﬁnished anticancer
therapy were specially designed for data retrieval. These
forms represent a legal document of the mandatory annual
report from pediatricians of municipal districts. Follow-
up information was collected by active search in hospital
databases and by passive retrieval of notiﬁcation form ﬁlled
by primary care pediatricians. Identiﬁable death certiﬁcates
were not available to the registry. Depersonalized cancer
mortality database of MR was used, and special requests are
sent to primary care pediatricians to trace back other records
for these patients. The completeness of registration exceeded
90%.
Foreachregisteredcase,informationincludedcivilstatus
proﬁle (name, surname, gender, date of birth, and address at
the time of cancer diagnosis) and disease proﬁle (incidence
date, primary site and histology, diagnostic basis, stage, and
type of therapy). Diagnoses were conﬁrmed by reference
pathology laboratory in all cases. None of the cases were
registered from death certiﬁcate only. Multiple primary
tumors in the same patient were separately registered. The
localization of the primary tumor and histological type
was deﬁned in accordance to International Classiﬁcation
of Diseases for Oncology (ICD-O), 3rd edition [5]. Sub-
sequently, tumors were grouped according to International
Classiﬁcation of Childhood Cancer, 3rd ed. (ICCC-3) [6].
ICCC-3 refers STS to IX diagnostic group divided into 5
subgroups: IXa: RMS, IXb: ﬁbrosarcomas, peripheral nerve
sheath tumors, and other ﬁbrous neoplasms (further in text-
subgroup of “ﬁbrosarcoma”), IXc: Kaposi sarcoma, IXd:
other speciﬁed STS, and IXe: unspeciﬁed STS. For further
analysis, STSs were divided into RMS (IXa subgroup) and
NRSTS (IXb, IXc, IXd, and IXe subgroups) [6].
Table 1: Deﬁnition of the topographic categories of STS.
Site of primary tumor ICD-O-3 topography code [5]
Head and neck
C00.0–C14.8, C30.0–C32.9,
C41.0–C41.1, C44.0, C44.2–C44.4,
C47.0, C49.0, C76.0
Orbit C69.0–C69.9, C44.1
Pelvis C41.4, C47.5, C49.5, C76.3
Genitourinary system
C51.0–C57.9, C60.0–C60.9, C61.9,
C62.0–C63.9, C64.9–C66.9,
C67.0–C67.9, C68.0–C68.9
Thorax C49.3, C76.1
Limbs C40.0–C40.9, C44.6, C44.7, C47.1,
C47.2, C49.1, C49.2, C76.4, C76.5
Not otherwise speciﬁed C76.2, C76.7, C76.8, C80.9 and C49.9
Others All codes not listed in another
category
Forclassiﬁcationoftheprimarytumorlocalization,ICD-
O-3 topography code was grouped in 8 sites [7]( Table 1).
Most of the registered patients (45/68, 66,2%) were
treated according to consecutive protocols of the Coop-
e r a t i v eS o f tT i s s u eS a r c o m aS t u d yG r o u p( C o o p e r a t i v e
Weichteilsarkom-Studie, CWS) of the German Society of
Pediatric Oncology and Haematology (GPOH) [8]. The rest
of the patients received anticancer treatment according to
institutional protocols that included multiagent chemother-
apy, radiation therapy, and surgery.
Annual population estimates in MR were based on the
data of RF population census in 2002 and were received
from Moscow Regional Committee of Federal State Statistics
Service. The average annual population in the given period
was 876.695 (95% CI: 843.717 to 909.673) for children
aged 0–14 years. A decrease in childhood population from
976.795 in 2000 to 868.932 in 2009 was observed during the
study period. Crude annual incidence rate was calculated
per 100.000 children/year. Age-standardized incidence rate
(ASR) was calculated by direct method per 100.000 chil-
dren/year using the World Standard Population [9]. Crude
incidence rate and ASR were calculated for children 0–
14 years old. Age-speciﬁc incidence rate was calculated for
four diﬀerent age groups: <1, 1–4, 5–9, and 10–14 years.
Kaplan-Meier method was used for survival analyses [10].
Observed survival was calculated for the entire group of
patients, for the age groups 0–4, 5–9, 10–14 years, and
separately for patients with RMS and NRSTS. Diﬀerences in
survival rates between various patient groups were evaluated
by comparison of entire survival curves and tested with
the log-rank tests. Fisher’s exact test was used to compare
categorical variables due to small number of cases. Statistica
8.0(Statsoft,USA)wasusedforstatisticalanalysisofthedata.
3. Results
Sixty-eight cases of STS in children 0–14 years old were
registered in 2000–2009, comprising 5,8% of all malignant
tumors in this age group. STS was the third most frequentSarcoma 3
extracranial solid tumor in children after neuroblastoma
and renal tumors. There was a slight male prevalence with
the male-to-female ratio which was 1,52:1. Most cases
were observed in 10–14 age group (22 patients, 32,4%). 20
(29,4%) and 16 (23,5%) cases were registered in 1–4 and 5–
9 age groups, respectively. The smallest number of patients
was registered in infants—10 (14,7%) cases. The median age
at diagnosis was 5 years.
Distribution of STS by diagnostic subgroup according
to ICCC-3 showed the prevalence of subgroup “RMS”
(Table 2),followedbysubgroupsof“otherspeciﬁedSTS”and
“ﬁbrosarcoma”. Kaposi sarcoma cases were not identiﬁed.
RMS was the most common histological type of STS,
representing 54,4% of cases. Among NRSTS there were 8
(11,8%) cases of sinovial sarcoma, 7 (10,3%) malignant
peripheral nerve sheath tumor, and 5 (7,4%) cases of
Ewing sarcoma family. Analysis of distribution of STS
cases according to age demonstrated a negative correlation
between number of RMS and patient’s age: RMS comprised
70% of STS cases in infants and 80% in children 1–4 years of
age, but only 23% in 10–14-year age group.
Location of primary tumor diﬀered between RMS and
NRSTS. Majority of RMS (43.3%) was located in the head
and neck region (including orbit) whereas NRSTS mainly
aﬀected limbs (45.2%) (Table 3).
The crude incidence rate of STS in children 0–14
years old was 0,78 ASR was 0,81 per 100.000 children/year
(Table 2). The highest age-speciﬁc incidence rate was
observed in infants—1,76 per 100.000 children/year. Inci-
d e n c er a t eo fS T Ss u b g r o u p sv a r i e di nd i ﬀerent age groups.
Age-speciﬁc incidence rate of RMS (IXa) was the highest
in infants, decreasing in older age groups. Incidence rate
of “other speciﬁed STS” (IXd) showed bimodal distribution
with the highest incidence observed in infants and children
10–14 years old.
Cancer predisposition syndromes presented by neuroﬁ-
bromatosis type 1 were observed in 3 (4,4%) cases. In 1
case RMS developed as a second malignant neoplasm in
the radiation ﬁeld 3,4 years after the diagnosis of hereditary
retinoblastoma.
T h eO So fa l lp a t i e n t sw i t hS T Sa t5y e a r sw a s6 4 , 1( 9 5 %
CI 55,0–73,2) (Figure 1).
There was no statistically signiﬁcant diﬀerence in 5-year
OS between RMS—59,2 (95% CI 47,0–71,4) and NRSTS—
69,3 (95% CI 55,8–82,8) (P = 0,63) (Figure 2).
The better 5-year OS rate was observed in patient 5–9
years of age 80,0% (95% CI 62,5–97,5). The 5-year OS for
patients0–4and10–14yearsofagewas58,3%(95%CI44,8–
71,8), and 62,3% (95% CI 46,3–78,3), respectively. Five-year
OS in age groups <1, 1–9 and >10 years was 50,0% (95% CI
28,1–71,9), 70,0% (95% CI 57,5–82,5) and 62,2% (95% CI
46,3–78,1), respectively. Diﬀerence in survival between age
groups was not statistically signiﬁcant.
4. Discussion
ThepresentstudydescribestheincidenceandsurvivalofSTS
in children in MR, the second most populated region of RF.
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Figure 1: Observed survival, all patients. OS = 64,1 (95% CI 55,0–
73,2) at 5 years.
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Figure 2: Observed survival, RMS versus NRSTS. OS for RMS =
59,2 (95% CI 47,0–71,4) at 5 years. OS for NRSTS = 69,3 (95% CI
55,8–82,8).
Epidemiology studies of childhood cancer are hampered by
the lack of population-based cancer registries in Russia. This
studyistheﬁrstpublishedreportpresentingdetailedanalysis
of epidemiological characteristics of STS in children in RF.
Childhood population-based cancer registry data were used
for analysis that precludes selection bias, typical for hospital-
based studies.
Children <15 years of age were included. It should be
noted that in the literature diﬀerent age intervals for the
deﬁnition of “pediatric” population are used. Ferrari et al.
[11] use this term for cases aged <20 years. On the contrary,
Automated Childhood Cancer Information System (ACCIS)
in Europeseparatelyanalyzescasesin children0–14 yearsold
and adolescents 15–19 years old [12].
The incidence of STS in children varies considerably
depending on geographic region and ethnic group [2].4 Sarcoma
Table 2: Absolute number of cases, crude, ASR, and age-speciﬁc incidence rate of soft tissue sarcomas by ICCC-3 in children (0–14 years)
diagnosed in Moscow Region in 2000–2009.
N %
Incidence rate (per 100.000 children per year)
M/F ratio Age speciﬁc
Crude1 ASR
<1 1–4 5–9 10–14
IX soft tissue sarcomas 68 100 1,76 0,95 0,61 0,63 0,78 0,81 1,52
IXa rhabdomyosarcomas 37 54,40 1,23 0,76 0,35 0,14 0,42 0,48 2,08
IXb ﬁbrosarcoma 8 11,80 0,00 0,00 0,12 0,14 0,09 0,08 1,67
IXc kaposi sarcoma 0 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
IXd other speciﬁed STS 22 32,40 0,35 0,19 0,15 0,34 0,25 0,24 1,00
IXe unspeciﬁed STS 1 1,40 0,18 0,00 0,00 0,00 0,01 0,01 0,00
1The sum does not correspond to 0,78 due to rounding in calculations.
Table 3: Frequency and percentage of STS by site and histology.
Site of tumor
All STS RMS NRSTS RMS versus NRSTS
N % N % N %
(Fisher’s exact test)
Head and neck 17 25,0 11 29,8 6 19,3 n.s.2
Orbit 5 7,3 5 13,5 0 0 n.s.
Pelvis 8 11,8 6 16,2 2 6,5 n.s.
Genitourinary system 6 8,8 6 16,2 0 0 P = 0,0279
Limbs 17 25,0 3 8,1 14 45,2 P = 0,0005
Thorax 4 5,9 1 2,7 3 9,7 n.s.
Others 10 14,7 4 10,8 6 19,3 n.s.
NOS1 1 1,5 1 2,7 0 0 n.s.
Total 68 100,0 37 100,0 31 100,0
1NOS: non otherwise speciﬁed; 2n.s.: not signiﬁcant.
In general, higher incidence rates were observed in Europe
and North America, lower ones in Asian countries. Data
from the International Agency for Research on Cancer
(IARC) showed that incidence rate of STS in Caucasians
children varied from 0,5 to 0,9 per 100.000 per year [2].
AccordingtoACCISaverageincidencerateofSTSinchildren
<15 years in Europe is 0.91 per 100.000 per year, and it varies
between 5 geographic regions [12]. The highest incidence
rate of STS is observed in Northern countries (1,1 per
100.000 children per year), the lowest in Eastern Europe
(0.84 per 100.000 children per year). The cause of these
geographical diﬀerences is not clear; however, the impact
of variations in diagnostic, classiﬁcation, and registration
criteria could not be ruled out [12]. The incidence rate
of STS obtained in our study (0,81 per 100.000 children
per year) was comparable to the data of the Eastern
European countries included in ACCIS project. It reﬂects
thecompletenessofchildhoodSTSregistrationbychildhood
population-based cancer registry in MR.
Certain congenital anomalies and genetic conditions
(e.g., Li-Fraumeni syndrome, neuroﬁbromatosis type I) are
known as the strongest risk factors, although they explain
only a small proportion of cases [3, 13]. Thus, Narod et al.
reported cancer predisposition syndromes in 20 (2,0%) out
of 1003 children with STS in Great Britain [14]. Radiation
therapy is the best-known environmental risk factor for
STS [15]. HIV infection is responsible for cases of Kaposi’s
sarcomainAfrica[2].Kaposi’ssarcomamakesupabouttwo-
thirds of STS and 20% of all childhood cancers in some
African countries [16] but only 1% of STS in the US [3].
In our study genetic predisposition syndromes were
revealed in 4,4% cases and were presented by neuroﬁbro-
matosis type 1. In 1 patient with hereditary retinoblastoma
RMS developed as a second malignant neoplasm in the
radiation ﬁeld. No cases of Kaposi’s sarcoma in our study
were detected, which is consistent with the data of the
European and North American cancer registries, indicating
extreme rarity of the disease [3, 12].
The incidence rate of STS in children varies by age.
The highest incidence seen in infants (1,3–2,1 per 100.000)
gradually decreases to 0,6–0,8 per 100.000 per year in 5–9
year age group, with further increase to 0,72–1,1 per 100.000
per year in children older than 10 years [3, 12]. The results
of our study also corroborate with the previous ﬁndings: the
highest incidence observed in infants (1,76 per 100.000 per
year), the lowest in 5–9-year age group (0,61 per 100.000
per year). The biological basis of age-dependent diﬀerences
in incidence rate is not clear. It is speculated that higher
STS incidence in young children could be a result of genetic
predisposition. Diller et al. in a study of 33 cases of sporadic
RMSshowedthat3of13childrenyoungerthan3yearsofage
at diagnosis (compared with none of the 20 children olderSarcoma 5
than3yearsofage)hadgermlinemutationsintheirp53gene
[17].
The distribution of speciﬁc subgroups of STS according
to ICCC-3 showed prevalence of RMS (IXa) and the
subgroup of “other speciﬁed STS” (IXd). The most extensive
studiesonSTSepidemiologyinchildren[2,3,12]wer ebased
on International Classiﬁcation of Childhood Cancer, 2d ed.
(ICCC-2) [18]. Several histological types (e.g., pleomorphic
malignant ﬁbrous histiocytoma) assigned to a subgroup
of “ﬁbrosarcoma” (IXb) in ICCC-2 were included into
s u b g r o u po f“ o t h e rs p e c i ﬁ e dS T S ”( I X d )[ 6]. It complicates
a comparative analysis of diﬀerent STS subgroups because
in our study tumors were stratiﬁed according to ICCC-3.
Nevertheless, recent report of German Childhood Cancer
Registry based on ICCC-3 [7] conﬁrmed our ﬁndings. RMS
and “other speciﬁed STS” were the two most common
groups of STS in children comprising 58,3% and 27,3%,
respectively [7]. RMS represents the single most common
histological type of STS in our childhood population. This
observation is consistent with the population-based data
from other countries [3, 7]. Age-related changes in ratio of
RMS and NRSTS identiﬁed in children in MR have been
previously described by others [3, 7, 12]. Data from German
Childhood Cancer Registry showed decreased percentage of
RMS in older age groups: 71, 64 and 34% in children 0–
4, 5–9, and 10–14 years of age, respectively [7]. Correlation
of histological tumor type with the topography of primary
tumor is well known [1]. As expected the most frequent
localization of RMS was the head and neck region, whereas
NRSTS predominantly aﬀected limbs.
Analysisofsurvivalofchildrenwithcanceratthepopula-
tion level is an extremely important index reﬂecting the
quality of specialized medical care. Data from ACCIS project
showed signiﬁcant diﬀerences in survival of children with
STS in Europe [12]. Thus, for the pooled European data
5-year survival of patients with STS diagnosed in 1988–
1997 years was 65%, ranging from 74% in Northern and
SouthernEuropeto50%inEasternEurope[12].Theaverage
survival rate of children with RMS in Europe was 63%,
with the lowest survival observed in Eastern Europe—40%.
In the recently published report of Eurocare project 5-year
survival of children with RMS in Eastern Europe was 64,9%
[19]. Data from the USA Surveillance Epidemiology and
End Results program (SEER) showed 5-year survival rate
of patients registered in 2001–2007, 72,9% for the entire
group of STS, and 68.1% for RMS [20]. 5-year survival of
children with STS, obtained in this study, was 64,1% for
the whole group of STS and 59,2% for RMS and was lower
in Western countries but compatible to the data from East
Europe. It should be noted that STS represents signiﬁcant
challenges for treatment and requires a multidisciplinary
approach to therapy. Protocol-based therapy of cancer in
children, including STS, was introduced in MR only in 2000,
that deﬁnitely has aﬀected treatment results obtained in
the present study. Age is an important prognostic factor in
STS, especially in RMS [1, 11, 12, 21]. The worst results
of therapy have been reported in infants and children over
10 years of age at the time of diagnosis. According to
ACCIS data the better survival was observed in children
aged 5–9-year (70%), whereas in other age groups survival
ranged from 57% in infants up to 64% in children aged 1–
4y e a r s[ 12]. In our study there was a trend towards better
survival of children in 5–9 years age group (5-year OS 80%),
but diﬀerence was not statistically signiﬁcant due to small
number of patients.
In conclusion, the present study provides the ﬁrst data
on incidence and survival of STS in children in RF. The
epidemiological pattern of the disease is compatible with
the data from Europe and North America. Small number of
patients is one of the main limitations of this study. On the
contrary, strength of this analysis includes population-based
data and accuracy of the data conﬁrmed by microscopic
veriﬁcationinallcases,lackofdeathcertiﬁcatecases,andlow
number of patients assigned to the subgroup “unspeciﬁed
STS”. The obtained data can form a basis for development of
population cancer control programs for children with cancer
in other regions of RF.
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